FerGene announces pivotal Phase 3 study of nadofaragene firadenovec met its primary endpoint with more than half of patients with high-grade non-muscle invasive bladder cancer (CIS ± Ta/T1) achieving a complete response at three months
SUO 2019 FerGene, a new gene therapy company formed by Ferring Pharmaceuticals and Blackstone Life Sciences, positive results from the pivotal Phase 3 clinical trial evaluating nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy, for the treatment of high-grade, BCG unresponsive non-muscle invasive bladder cancer
